Anzeige
Mehr »
Samstag, 04.07.2026 - Börsentäglich über 12.000 News
Neben Europas Lithium-Gigant: Hebt dieser 8,8-Mio.-Nanocap jetzt ebenfalls ab?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W5SA | ISIN: US9224751084 | Ticker-Symbol: VEE
Tradegate
03.07.26 | 19:48
167,60 Euro
-0,36 % -0,60
Branche
Software
Aktienmarkt
S&P 500
1-Jahres-Chart
VEEVA SYSTEMS INC Chart 1 Jahr
5-Tage-Chart
VEEVA SYSTEMS INC 5-Tage-Chart
RealtimeGeldBriefZeit
167,85168,5503.07.
167,60168,8003.07.
PR Newswire
669 Leser
Artikel bewerten:
(2)

Veeva Systems: More Than 450 Companies Drive Speed to Market with Veeva RIM

Advanced regulatory capabilities and new industry partnerships accelerate collaboration with global health authorities

BARCELONA, Spain, Sept. 2, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced more than 450 companies, including 19 of the top 20 biopharmas, have adopted Veeva RIM for regulatory information management (RIM) on a unified platform. Continued innovation to advance connectivity now includes partnerships with Accumulus Technologies and DNAnexus, enabling integration with multi-health authority platforms to drive efficiency and compliance.

"Regulatory teams are adopting new Veeva product innovations to continually improve efficiency and reduce cycle times. Strengthened by industry partnerships, Veeva RIM provides an end-to-end solution that accelerates time to market, improves global stakeholder collaboration, and enables seamless data flow in a rapidly evolving regulatory environment," said Marc Gabriel, vice president, regulatory at Veeva.

Companies using Veeva RIM applications can streamline processes across all steps of the regulatory lifecycle. With Veeva Submissions Publishing, more than 85 organizations are using continuous publishing to reduce rework and remove bottlenecks, accelerating submission timelines.

"Our strategic partnership will connect the Accumulus platform and Veeva RIM for greater interoperability to modernize how information is instantly and simultaneously shared with our growing network of over 70 regulatory agencies worldwide. By facilitating seamless regulatory submissions, we can empower our mutual customers to get treatments to patients faster," said Francisco Nogueira, CEO of Accumulus Technologies.

"Integrating DNAnexus Trusted Regulatory Spaces (TRS) and Veeva RIM will provide best-in-class data sharing capabilities for inter-agency collaboration and faster regulated product approvals," said Thomas Laur, CEO of DNAnexus.

Veeva RIM streamlines global regulatory processes on a single, cloud-based platform. It is part of Veeva Development Cloud, the technology foundation for product development across clinical, quality, regulatory, and safety. To learn more about Veeva RIM, visit veeva.com/eu/RIM.

About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:
Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo_v2.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/more-than-450-companies-drive-speed-to-market-with-veeva-rim-302542550.html

© 2025 PR Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.